Patents Assigned to American Cyanamid Company
  • Reversal of multidrug resistance in human colon carcinoma cells
    Publication number: 20030083230
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Application
    Filed: February 28, 2002
    Publication date: May 1, 2003
    Applicant: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger
  • 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrroldine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Publication number: 20030083364
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: August 23, 2002
    Publication date: May 1, 2003
    Applicant: American Cyanamid Company
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • Methods for somatic embryo formation and plant regeneration of Beta vulgaris
    Patent number: 6555375
    Abstract: The present invention relates to plant tissue culture methods, particularly for Beta vulgaris. Methods are provided for producing callus tissues, somatic embryos and plants. The methods find use in the field of agricultural biotechnology, particularly in the production of transgenic Beta vulgaris plants.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: April 29, 2003
    Assignee: American Cyanamid Company
    Inventor: Andrei E. Golovko
  • Sustained-release compositions for parenteral administration
    Patent number: 6552002
    Abstract: Sustained-release compositions comprising a macrolide compound, a surfactant, a co-solvent, and a solvent. The sustained-release compositions of this invention may be parenterally administered to animals, and are useful for preventing or treating helminth, acarid or arthropod endo- or ectoparasitic infection or infestation in warm-blooded animals for prolonged periods of time.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: April 22, 2003
    Assignee: American Cyanamid Company
    Inventors: William David Steber, Sivaja Ranjan
  • 5-Substituted-3(2H)-furanones useful for inhibition of farnesyl-protein transferase
    Publication number: 20030073736
    Abstract: Compounds of Formula (I): 1
    Type: Application
    Filed: August 23, 2002
    Publication date: April 17, 2003
    Applicant: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Irwin Hollander, Ann Aulabaugh
  • Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
    Patent number: 6548496
    Abstract: This invention provides compounds of formula I having the structure Wherein substitutions at A″, Z, n, and X are set forth in the specification.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: April 15, 2003
    Assignee: American Cyanamid Company
    Inventors: Allan Wissner, Philip R. Hamann, Ayako Yamashita
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    Patent number: 6548524
    Abstract: This invention provides, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-&agr; converting enzyme (TACE. tumor necrosis factor-&agr; converting enzyme) which arc useful for the treatment of diseases in which these enzymes are implicated.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: April 15, 2003
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Vasopressin antagonist and diuretic combination
    Publication number: 20030069227
    Abstract: This invention provides methods of increasing urine flow in humans while minimizing the loss of electrolytes or ions, the methods comprising administering to a human in need thereof a combination of N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide (or a pharmaceutically acceptable salt thereof), also known as VPA-985, and one or more diuretic agents, as well as pharmaceutical compositions and kits or packages for such combinations.
    Type: Application
    Filed: June 4, 2002
    Publication date: April 10, 2003
    Applicant: American Cyanamid Company
    Inventors: Evelyn Ellis-Grosse, Gayle P. Orczyk
  • 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
    Patent number: 6544984
    Abstract: Compounds having the following formula:   are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: April 8, 2003
    Assignee: American Cyanamid Company
    Inventors: Jay Donald Albright, Efren Guillermo Delos Santos, Jeremy Ian Levin, James Ming Chen
  • Substantially pure glycopeptide antibotics AC-98-1; AC-98-2; AC-98-3; AC-98-4 AND AC-98-5
    Publication number: 20030054508
    Abstract: The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus.
    Type: Application
    Filed: April 25, 2002
    Publication date: March 20, 2003
    Applicant: American Cyanamid Company
    Inventors: Guy Thomas Carter, Haiyin He
  • Antibiotics AA-896
    Publication number: 20030054983
    Abstract: This invention relates to antibiotic compounds AA896 of the formula 1
    Type: Application
    Filed: April 25, 2002
    Publication date: March 20, 2003
    Applicant: American Cyanamid Company
    Inventors: Yang-I Lin, Zhong Li, Gerardo DelaCruz Francisco, Leonard Alexander McDonald
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Patent number: 6534491
    Abstract: This invention provides, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stroinelysins and collagenases) and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr;converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: March 18, 2003
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Pour-on formulations effective for the control of internal and external parasites of homothermic animals
    Patent number: 6514951
    Abstract: There are provided non-aqueous pour-on, water-fast formulations effective for the control of internal and external parasitic infections and infestations of homothermic animals such as mammalian quadrupeds. The pour-on formulations of the present invention contain as the active ingredient, a compound selected from the group consisting of LL-F28249&agr;-&lgr;, 23-oxo (keto) and 23-imino derivatives of the compounds collectively defined as LL-F28249, and milbemycin and avermectin molecules.
    Type: Grant
    Filed: July 6, 1993
    Date of Patent: February 4, 2003
    Assignee: American Cyanamid Company
    Inventors: Irwin B. Wood, James Quinlan
  • N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and, methods related thereto
    Publication number: 20020198221
    Abstract: N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide, and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Compositions containing N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide, as well as pharmaceutically acceptable salts thereof, are also disclosed.
    Type: Application
    Filed: December 21, 2001
    Publication date: December 26, 2002
    Applicant: American Cyanamid Company
    Inventors: John P. Dusza, Andrew S. Tomcufcik, Jay D. Albright, Bernard Beer
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Patent number: 6498167
    Abstract: This invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula (B) as shown herein or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: December 24, 2002
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Publication number: 20020188120
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Application
    Filed: June 28, 2002
    Publication date: December 12, 2002
    Applicant: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, Jannie Lea Baker
  • 6-(spirocyclopropyl) penicillanic acid 4, 4-dioxides
    Patent number: 6489316
    Abstract: The 6-(spirocyclopropyl)-penicillanic acid 4,4-dioxides of the general Formula (I): as defined herein above which exhibit beta-lactamase inhibiting activity, use of such compounds in combination with beta-lactam antibiotics for inhibiting beta-lactamases, pharmaceutical compositions and processes for preparing such compounds.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: December 3, 2002
    Assignee: American Cyanamid Company
    Inventors: Vincent P. Sandanayaka, Amarnauth S. Prashad
  • Synergistic ectoparasiticidal methods and compositions
    Patent number: 6479537
    Abstract: The present invention provides methods for synergistic control of ectoparasitic arthropods with a synergistically effective amount of a combination of the macrocyclic lactone moxidectin and an arylpyrrole compound. Also provided are methods of protecting animals from infestation and attack by ectoparasites with said combination. The present invention also provides synergistic insecticidal compositions comprising as essential active ingredients the macrocyclic lactone moxidectin and an arylpyrrole compound.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: November 12, 2002
    Assignee: American Cyanamid Company
    Inventors: Kathleen Heaney, Mary E. Doscher, Douglas Rugg
  • Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
    Publication number: 20020165229
    Abstract: This invention provides compounds of formula I having the structure 1
    Type: Application
    Filed: December 21, 2001
    Publication date: November 7, 2002
    Applicant: American Cyanamid Company
    Inventors: Allan Wissner, Philip R. Hamann, Ayako Yamashita
  • Reversal of multidrug resistance in human colon carcinoma cells
    Publication number: 20020156015
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Application
    Filed: February 28, 2002
    Publication date: October 24, 2002
    Applicant: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Maya Prakash Singh, Lee Martin Greenberger